CN Patent

CN105255927B — 一种kiaa1217-ret融合基因

Assigned to First Affiliated Hospital of Wenzhou Medical University · Expires 2018-07-27 · 8y expired

What this patent protects

本发明公开了一种KIAA1217‑RET融合基因，该KIAA1217‑RET融合基因由KIAA1217基因的第1‑11号外显子和RET基因的第8‑19号外显子相融合组成，其核苷酸序列如附图1所示。该融合基因的公开有助于进一步探究甲状腺癌中所未发现驱动基因改变，优化甲状腺乳头状癌患者的临床病理分类和诊治策略。

USPTO Abstract

本发明公开了一种KIAA1217‑RET融合基因，该KIAA1217‑RET融合基因由KIAA1217基因的第1‑11号外显子和RET基因的第8‑19号外显子相融合组成，其核苷酸序列如附图1所示。该融合基因的公开有助于进一步探究甲状腺癌中所未发现驱动基因改变，优化甲状腺乳头状癌患者的临床病理分类和诊治策略。

Drugs covered by this patent

Patent Metadata

Patent number
CN105255927B
Jurisdiction
CN
Classification
—
Expires
2018-07-27
Drug substance claim
No
Drug product claim
No
Assignee
First Affiliated Hospital of Wenzhou Medical University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.